Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effects.
Thromb Res
; 55(4): 419-26, 1989 Aug 15.
Article
em En
| MEDLINE
| ID: mdl-2554524
ABSTRACT
With the recent development of numerous low molecular weight heparins (LMWHs), a certain amount of concern has become evident as to the equivalency of each agent. In a comprehensive study, we have taken the seven available LMWHs to directly compare their in vitro and in vivo (subcutaneous) antithrombotic properties in one laboratory setting. Where possible, various batches of one LMWH were evaluated. Our findings were that variations of in vivo activity were observed between the LMWHs studied. Some activities were significantly different from placebo, whereas others were not. Depending on the assay chosen significant differences could also be observed for the in vitro activity.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tromboflebite
/
Heparina de Baixo Peso Molecular
/
Fibrinólise
Limite:
Animals
Idioma:
En
Revista:
Thromb Res
Ano de publicação:
1989
Tipo de documento:
Article
País de afiliação:
França